Cargando…
Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007
BACKGROUND & OBJECTIVE: Bladder cancer is the fourth most common cancer in men and the most common cancer in women, comprising 8% of all males and 3% of female tumors. The present study aimed to estimate the five-year survival rates of bladder cancer in Iran. METHODS: Information on 3,337 regist...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iranian Society of Pathology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691705/ https://www.ncbi.nlm.nih.gov/pubmed/33391383 http://dx.doi.org/10.30699/ijp.2020.118375.2287 |
_version_ | 1783614350630584320 |
---|---|
author | Khayamzadeh, Maryam Aliakbari, Fereshte Zolghadr, Zahra Emadeddin, Majid Ahadi, Mahsa Akbari, MohammadEsmaeil Abedi, Amir Reza Nematollahi, Shahrzad Hosseini, Jalil |
author_facet | Khayamzadeh, Maryam Aliakbari, Fereshte Zolghadr, Zahra Emadeddin, Majid Ahadi, Mahsa Akbari, MohammadEsmaeil Abedi, Amir Reza Nematollahi, Shahrzad Hosseini, Jalil |
author_sort | Khayamzadeh, Maryam |
collection | PubMed |
description | BACKGROUND & OBJECTIVE: Bladder cancer is the fourth most common cancer in men and the most common cancer in women, comprising 8% of all males and 3% of female tumors. The present study aimed to estimate the five-year survival rates of bladder cancer in Iran. METHODS: Information on 3,337 registered cases of bladder cancer was obtained from the Office of National Cancer Registry in the Ministry of Health and Medical Education (MOH & ME). A telephone survey was conducted to gather additional information, such as survival status, demographic, and clinical profile. Kaplan–Meier estimates of five-year survival rates were calculated according to the age of diagnosis, gender, pathological type, and provincial pole. RESULTS AND CONCLUSION: Overall five-year survival rate was 77%. According to the pathologic type, five-year survival rates were 81%, 66%, 81%, 42%, 77%, and 82% in low-grade urothelial carcinoma, high-grade urothelial carcinoma, adenocarcinoma, undifferentiated carcinomas, Squamous Cell Carcinomas (SCCs), and other tumors, respectively. Additionally, those tumors were 93%, 88%, 81%, 64%, and 44% among patients whose average ages at diagnosis were < 50, 50–59, 60–59, 70–79, and > 80 years old, respectively. Our study revealed that age and histological type were the major prognostic factors for survival in patients with bladder cancer. Therefore, given the histologic features of the tumor and patients with advanced age, a continuous screening would be highly warranted. |
format | Online Article Text |
id | pubmed-7691705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Iranian Society of Pathology |
record_format | MEDLINE/PubMed |
spelling | pubmed-76917052021-01-01 Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007 Khayamzadeh, Maryam Aliakbari, Fereshte Zolghadr, Zahra Emadeddin, Majid Ahadi, Mahsa Akbari, MohammadEsmaeil Abedi, Amir Reza Nematollahi, Shahrzad Hosseini, Jalil Iran J Pathol Short Communication BACKGROUND & OBJECTIVE: Bladder cancer is the fourth most common cancer in men and the most common cancer in women, comprising 8% of all males and 3% of female tumors. The present study aimed to estimate the five-year survival rates of bladder cancer in Iran. METHODS: Information on 3,337 registered cases of bladder cancer was obtained from the Office of National Cancer Registry in the Ministry of Health and Medical Education (MOH & ME). A telephone survey was conducted to gather additional information, such as survival status, demographic, and clinical profile. Kaplan–Meier estimates of five-year survival rates were calculated according to the age of diagnosis, gender, pathological type, and provincial pole. RESULTS AND CONCLUSION: Overall five-year survival rate was 77%. According to the pathologic type, five-year survival rates were 81%, 66%, 81%, 42%, 77%, and 82% in low-grade urothelial carcinoma, high-grade urothelial carcinoma, adenocarcinoma, undifferentiated carcinomas, Squamous Cell Carcinomas (SCCs), and other tumors, respectively. Additionally, those tumors were 93%, 88%, 81%, 64%, and 44% among patients whose average ages at diagnosis were < 50, 50–59, 60–59, 70–79, and > 80 years old, respectively. Our study revealed that age and histological type were the major prognostic factors for survival in patients with bladder cancer. Therefore, given the histologic features of the tumor and patients with advanced age, a continuous screening would be highly warranted. Iranian Society of Pathology 2021 2020-10-10 /pmc/articles/PMC7691705/ /pubmed/33391383 http://dx.doi.org/10.30699/ijp.2020.118375.2287 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Khayamzadeh, Maryam Aliakbari, Fereshte Zolghadr, Zahra Emadeddin, Majid Ahadi, Mahsa Akbari, MohammadEsmaeil Abedi, Amir Reza Nematollahi, Shahrzad Hosseini, Jalil Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007 |
title | Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007 |
title_full | Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007 |
title_fullStr | Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007 |
title_full_unstemmed | Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007 |
title_short | Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007 |
title_sort | five-year survival rate of bladder cancer in iran during 2001-2007 |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691705/ https://www.ncbi.nlm.nih.gov/pubmed/33391383 http://dx.doi.org/10.30699/ijp.2020.118375.2287 |
work_keys_str_mv | AT khayamzadehmaryam fiveyearsurvivalrateofbladdercanceriniranduring20012007 AT aliakbarifereshte fiveyearsurvivalrateofbladdercanceriniranduring20012007 AT zolghadrzahra fiveyearsurvivalrateofbladdercanceriniranduring20012007 AT emadeddinmajid fiveyearsurvivalrateofbladdercanceriniranduring20012007 AT ahadimahsa fiveyearsurvivalrateofbladdercanceriniranduring20012007 AT akbarimohammadesmaeil fiveyearsurvivalrateofbladdercanceriniranduring20012007 AT abediamirreza fiveyearsurvivalrateofbladdercanceriniranduring20012007 AT nematollahishahrzad fiveyearsurvivalrateofbladdercanceriniranduring20012007 AT hosseinijalil fiveyearsurvivalrateofbladdercanceriniranduring20012007 |